Karyopharm Therapeutics, Inc. KPTI

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Selinexor Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of the selinexor market across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers selinexor's approved indications, including multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL), alo

Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of August 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nas

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis. Karyopharm requested Priority Review of the application, which, if granted, could result in a six-month review process.

On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands […]

Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call

Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the second quarter of 2026 and provided an update on the Company's myelofibrosis program. Following continued constructive engagement with the U.S. Food and Drug Administration (FDA), the Company remains on track to submit its planned supplemental New Drug Application (sNDA) in August under the Accelerated Approval pathway for selinexor in

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates.

Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in underserved regionsDublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Endometrial Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. Global Endometrial Cancer Market Forecast to Reach US